Analysts expect Theravance Biopharma, Inc. to report revenue of 22.41 M for Q3 26, against a range of 21.50 M to 23.31 M. The most recent reported quarter, Q2 26, came in at 20.73 M, a 10.0% miss against the 23.03 M consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 16.87 M | 18.75 M | 15.39 M | 26.20 M | 19.99 M | 45.89 M | 17.70 M | 20.73 M | - | - | - | - | - | - | - | - | ||||||||||
| High Estimate | 16.98 M | 19.92 M | 15.30 M | 28.35 M | 21.78 M | 58.35 M | 19.48 M | 25.30 M | 23.31 M | 23.38 M | 24.37 M | 32.29 M | 27.48 M | 37.50 M | 24.01 M | 28.46 M | ||||||||||
| Low Estimate | 15.81 M | 16.31 M | 14.11 M | 24.77 M | 19.72 M | 49.32 M | 16.86 M | 20.75 M | 21.50 M | 21.98 M | 21.44 M | 26.57 M | 25.60 M | 33.09 M | 20.05 M | 25.65 M | ||||||||||
| Consensus Estimate | 16.39 M | 18.12 M | 14.70 M | 26.56 M | 20.75 M | 53.83 M | 18.17 M | 23.03 M | 22.41 M | 22.68 M | 22.91 M | 29.43 M | 26.54 M | 35.30 M | 22.03 M | 27.05 M |
Analysts expect Theravance Biopharma, Inc. to report earnings per share of 0.26 for Q3 26, against a range of 0.24 to 0.28. The most recent reported quarter, Q2 26, came in at -0.11, a 257.1% miss against the 0.07 consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -0.26 | -0.31 | -0.27 | 1.08 | 0.07 | 1.15 | -0.10 | -0.11 | - | - | - | - | - | - | - | - | ||||||||||
| High Estimate | -0.22 | -0.19 | -0.20 | 0.75 | -0.11 | 1.12 | 0.03 | 0.07 | 0.28 | 2.15 | 0.29 | 0.43 | 0.18 | 1.99 | 0.14 | 0.19 | ||||||||||
| Low Estimate | -0.26 | -0.23 | -0.24 | 0.63 | -0.13 | 0.94 | 0.03 | 0.07 | 0.24 | 1.93 | 0.25 | 0.37 | 0.16 | 1.69 | 0.12 | 0.17 | ||||||||||
| Consensus Estimate | -0.24 | -0.21 | -0.22 | 0.69 | -0.12 | 1.03 | 0.03 | 0.07 | 0.26 | 2.04 | 0.27 | 0.40 | 0.17 | 1.84 | 0.13 | 0.18 |
Pull Wall Street consensus for Theravance Biopharma, Inc. (high, low and consensus estimates alongside reported actuals) into your own models and apps with the Business Quant Estimates API. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/estimates?ticker=TBPH&mode=revenue&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/estimates"
params = {"ticker": "TBPH", "mode": "revenue", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/estimates?ticker=TBPH&mode=revenue&api_key=YOUR_API_KEY");
const data = await res.json();